← Back to Search

Low Dose Ketamine Infusion (LDKI) for Blunt Chest Trauma

Phase 4
Waitlist Available
Led By Joseph Farhat, MD
Research Sponsored by North Memorial Health Care
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up time zero up to 48 hours of infusion, plus up to 48 hours after infusion stops
Awards & highlights

Study Summary

The goal of this Randomized controlled double-blinded trial is to compare the addition of a ketamine infusion to placebo, when added to standard care in adult blunt trauma patients with multiple rib fractures. The main question it aims to answer are: • addition of low dose ketamine infusion (LDKI) decreases narcotic use • does LDKI impact pulmonary complications, readmission, or hospital length of stay Participants will receive usual standard of care with up to 48 hours of LDKI or placebo. If there is a comparison group: Researchers will compare infusion of a saline infusion to LDKI to see if LDKI decreases need for narcotic analgesics use.

Eligible Conditions
  • Blunt Chest Trauma
  • Multiple Rib Fractures

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time zero up to 48 hours of infusion, plus up to 48 hours after infusion stops
This trial's timeline: 3 weeks for screening, Varies for treatment, and time zero up to 48 hours of infusion, plus up to 48 hours after infusion stops for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Morphine Mg Equivalents
Secondary outcome measures
ICU admission or hospital readmission
Pulmonary complications

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Low Dose Ketamine Infusion (LDKI)Experimental Treatment1 Intervention
Infusion Bag will receive 100 mg of ketamine (Ketamine Infusion Subject). The Study Drug Bag will be released with a label that includes: Name of Study, Study Subject #, Patient Name, Pt MR#, Pt DOB, and INFUSION RATE. (Note: infusion rate is 0.1 mg/kg/hr and concentration of standard ketamine infusion bag is 1 mg/mL. That is, 100 mg of ketamine added to 100 mL saline).
Group II: Placebo/ControlPlacebo Group1 Intervention
Pharmacist will check randomization schedule. For placebo/control subject they will prepare an infusion bag of saline with no added medication. The Study Drug Bag will be released with a label that includes: Name of Study, Study Subject #, Patient (Pt) Name, Pt Medical record number (MR#), Pt Date of birth (DOB), and INFUSION RATE.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution
2021
Completed Phase 4
~50

Find a Location

Who is running the clinical trial?

North Memorial Health CareLead Sponsor
Michaela A West, MD, PhDStudy DirectorNorth Memorial Health
Joseph Farhat, MDPrincipal InvestigatorNorth Memorial Health

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Low Dose Ketamine for Blunt Thoracic Trauma
Michaela A West 2021. "Low Dose Ketamine for Blunt Thoracic Trauma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06236113.
~14 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top